A phase Ib study of the Akt inhibitor GDC-0068 with docetaxel (D) or mFOLFOX-6 (F) in patients (pts) with advanced solid tumors

被引：0
|
作者：
Saura, Cristina
Jones, Suzanne
Mateo, Joaquin
Hollebecque, Antoine
Cleary, James M.
Perez, Desamparados Roda
Zhu, Jin
Musib, Luna C.
Patel, Premal H.
Cervantes-Ruiperez, Andres
Isakoff, Steven J.
Soria, Jean-Charles
Molife, L. Rhoda
Tabernero, Josep
Bendell, Johanna C.
机构：
[1] Vall dHebron Univ Hosp, Dept Med Oncol, Barcelona, Spain
[2] Sarah Cannon Res Inst, Nashville, TN USA
[3] Royal Marsden Hosp, Surrey, England
[4] Inst Canc Res, Surrey, England
[5] Inst Gustave Roussy, Villejuif, France
[6] Dana Farber Canc Inst, Boston, MA 02115 USA
[7] Hosp Clin, Dept Med Oncol, Colorectal Unit, Dept Surg, Valencia, Spain
[8] Genentech Inc, San Francisco, CA 94080 USA
[9] Univ Valencia, Dept Hematol & Med Oncol, INCLIVA, Valencia, Spain
[10] Massachusetts Gen Hosp, Boston, MA 02114 USA
[11] Sarah Cannon Res Inst Tennessee Oncol PLLC, Nashville, TN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3021
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Sunitinib in combination with mFOLFOX6 chemotherapy in patients with advanced solid tumors: A phase I study
    Leong, S.
    Eckhardt, S.
    Chan, E.
    Chow, L.
    VerMeulen, W.
    Camidge, D.
    Rothenberg, M.
    Chow Maneval, E.
    Chao, R.
    Lockhart, A.
    ANNALS OF ONCOLOGY, 2007, 18 : VII123 - VII123
  • [22] Clinical combination of the MEK inhibitor GDC-0973 and the PI3K inhibitor GDC-0941: A first-in-human phase Ib study in patients with advanced solid tumors
    Bendell, Johanna
    LoRusso, Patricia
    Kwak, Eunice
    Pandya, Susan
    Musib, Luna
    Jones, Cheryl
    De Crespigny, Alex
    Belvin, Marcia
    McKenzie, Meghan
    Gates, Mary R.
    Chan, Iris
    Shapiro, Geoffrey
    CANCER RESEARCH, 2011, 71
  • [23] A Phase Ib study of telatinib (BAY 57-9352), a VEGFR-2 inhibitor, in combination with docetaxel in patients with advanced solid tumors
    Shaw, Heather M.
    Molife, Rhoda
    Karavasilis, Vasilios
    Ong, Teng J.
    Tate, Laura
    Fong, Peter C.
    Yap, Tim A.
    Lal, Rohit
    Ludwig, Catherine
    Brendel, Erich
    Christensen, Olaf
    de Bono, Johann S.
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3437S - 3437S
  • [24] Phase I study of docetaxel and ifosfamide in patients with advanced solid tumors
    Pronk, L
    Shrijvers, D
    LocciTonelli, D
    Verweij, J
    VanOosterom, AT
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 961 - 961
  • [25] Phase I study on docetaxel and Gemcitabine in patients with advanced solid tumors
    Jaremtchuk, AV
    Zarba, JJ
    Ferro, A
    ANNALS OF ONCOLOGY, 1998, 9 : 138 - 139
  • [26] Phase Ib study of afatinib plus standard-dose cetuximab in patients (pts) with advanced solid tumors.
    Gazzah, Anas
    Boni, Valentina
    Soria, Jean-Charles
    Holgado, Esther
    Even, Caroline
    Kaci, Mahmoud Ould
    Nazabadioko, Serge
    Xue, Wenqiong
    Calvo, Emiliano
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [27] Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors
    A Craig Lockhart
    Todd M. Bauer
    Charu Aggarwal
    Carrie B. Lee
    R Donald Harvey
    Roger B. Cohen
    Farhad Sedarati
    Tsz Keung Nip
    Hélène Faessel
    Ajeeta B. Dash
    Bruce J. Dezube
    Douglas V. Faller
    Afshin Dowlati
    Investigational New Drugs, 2019, 37 : 87 - 97
  • [28] A PHASE IB COMBINATION STUDY OF RO4929097 (RO), A GAMMA-SECRETASE INHIBITOR, AND TEMSIROLIMUS (TEM) IN PATIENTS (PTS) WITH ADVANCED SOLID TUMORS
    Diaz-Padilla, I.
    Hotte, S. J.
    Ivy, S. P.
    Oza, A. M.
    Hirte, H. W.
    Razak, A. R. A.
    Chen, E. X.
    Garcia, I. Brana
    Siu, L.
    Bedard, P.
    ANNALS OF ONCOLOGY, 2012, 23 : 156 - 156
  • [29] Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors
    Lockhart, A. Craig
    Bauer, Todd M.
    Aggarwal, Charu
    Lee, Carrie B.
    Harvey, R. Donald
    Cohen, Roger B.
    Sedarati, Farhad
    Nip, Tsz Keung
    Faessel, Helene
    Dash, Ajeeta B.
    Dezube, Bruce J.
    Faller, Douglas V.
    Dowlati, Afshin
    INVESTIGATIONAL NEW DRUGS, 2019, 37 (01) : 87 - 97
  • [30] LOTUS: A randomized, phase II, multicenter, placebo-controlled study of ipatasertib (Ipat, GDC-0068), an inhibitor of Akt, in combination with paclitaxel (Pac) as front-line treatment for patients (pts) with metastatic triple-negative breast cancer (TNBC).
    Kim, Sung-Bae
    Tan, Antoinette R.
    Im, Seock-Ah
    Villanueva, Rafael
    Valero, Vicente
    Saura, Cristina
    Oliveira, Mafalda
    Isakoff, Steven J.
    Singel, Stina Mui
    Dent, Rebecca Alexandra
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345